{
  "DOI": "10.1038/s41431-021-00892-z",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-021-00892-z",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eNeurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) are rare conditions with pronounced variability of clinical expression. We aimed to reach consensus on the most important manifestations meriting the development of drug trials. The five-staged modified Delphi procedure consisted of two questionnaires and a consensus meeting for 40 NF experts, a survey for 63 patient representatives, and a final workshop. In the questionnaires, manifestations were scored on multiple items on a 4-point Likert scale. The highest average scores for NF experts deciding the ‘need for new treatment’ were for malignant peripheral nerve sheath tumour (MPNST) (4,0) and high grade glioma (HGG) (3,9) for NF1; meningioma (3,9) for NF2 and pain (3,9) for SWN. The patient representatives assigned high scores to all manifestations, with plexiform neurofibroma being highest in NF1 (4,0), vestibular schwannoma in NF2 (4,0), and pain in SWN (3,9). Twelve experts participated in the consensus meeting and prioritised manifestations. MPNST was ranked the highest for NF1, followed by benign peripheral nerve sheath tumours. Tumour manifestations received highest ranking in NF2, and pain was the most prominent problem for SWN. Patient representative ratings for NF1 were similar to the experts’ opinions, except that they ranked HGG as the most important manifestation. For NF2 and SWN, the patient representatives agreed with the experts. We conclude that NF experts and patient representatives consent to prioritise development of drug trials for MPNST, benign peripheral nerve sheath tumours, cutaneous manifestations and HGG for NF1; tumours for NF2; and pain for SWN.\u003c/jats:p\u003e",
  "alternative-id": [
    "892"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "15 October 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "6 April 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "8 April 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "26 April 2021"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare no competing interests."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0003-0928-4049",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Dhaenens",
      "given": "Britt A. E.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Ferner",
      "given": "Rosalie E.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Bakker",
      "given": "Annette",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Nievo",
      "given": "Marco",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-8482-5784",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Evans",
      "given": "D. Gareth",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wolkenstein",
      "given": "Pierre",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Potratz",
      "given": "Cornelia",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Plotkin",
      "given": "Scott R.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Heimann",
      "given": "Guenter",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Legius",
      "given": "Eric",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0001-7919-8934",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Oostenbrink",
      "given": "Rianne",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        4,
        26
      ]
    ],
    "date-time": "2021-04-26T05:02:36Z",
    "timestamp": 1619413356000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        11,
        2
      ]
    ],
    "date-time": "2023-11-02T18:42:48Z",
    "timestamp": 1698950568000
  },
  "funder": [
    {
      "DOI": "10.13039/501100010767",
      "award": [
        "853966",
        "853966",
        "853966",
        "853966",
        "853966",
        "853966"
      ],
      "doi-asserted-by": "publisher",
      "name": "Innovative Medicines Initiative"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        21
      ]
    ],
    "date-time": "2024-03-21T16:42:32Z",
    "timestamp": 1711039352146
  },
  "is-referenced-by-count": 6,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "11",
  "issued": {
    "date-parts": [
      [
        2021,
        4,
        26
      ]
    ]
  },
  "journal-issue": {
    "issue": "11",
    "published-print": {
      "date-parts": [
        [
          2021,
          11
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            4,
            26
          ]
        ],
        "date-time": "2021-04-26T00:00:00Z",
        "timestamp": 1619395200000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            4,
            26
          ]
        ],
        "date-time": "2021-04-26T00:00:00Z",
        "timestamp": 1619395200000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/s41431-021-00892-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-021-00892-z",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-021-00892-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1625-1633",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2021,
        4,
        26
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        4,
        26
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2021,
        11
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1016/B978-0-444-52891-9.00039-7",
      "author": "BR Korf",
      "doi-asserted-by": "publisher",
      "first-page": "333",
      "journal-title": "Handb Clin Neurol.",
      "key": "892_CR1",
      "unstructured": "Korf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333–40.",
      "volume": "111",
      "year": "2013"
    },
    {
      "author": "C Lu-Emerson",
      "first-page": "E47",
      "journal-title": "Rev Neurol Dis.",
      "key": "892_CR2",
      "unstructured": "Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009;6:E47–53.",
      "volume": "6",
      "year": "2009"
    },
    {
      "DOI": "10.1002/ajmg.a.33139",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "327",
      "journal-title": "Am J Med Genet A.",
      "key": "892_CR3",
      "unstructured": "Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327–32.",
      "volume": "152A",
      "year": "2010"
    },
    {
      "DOI": "10.1093/neuonc/nov200",
      "author": "JO Blakeley",
      "doi-asserted-by": "publisher",
      "first-page": "624",
      "journal-title": "Neuro Oncol.",
      "key": "892_CR4",
      "unstructured": "Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18:624–38.",
      "volume": "18",
      "year": "2016"
    },
    {
      "key": "892_CR5",
      "unstructured": "EU-PEARL. EU-PEARL (EU Patient-Centric Clinical Trial Platform). 2020. https://eu-pearl.eu/."
    },
    {
      "DOI": "10.1136/jnnp.2010.206532",
      "author": "RE Ferner",
      "doi-asserted-by": "publisher",
      "first-page": "82",
      "journal-title": "Pract Neurol",
      "key": "892_CR6",
      "unstructured": "Ferner RE. The neurofibromatoses. Pract Neurol. 2010;10:82–93.",
      "volume": "10",
      "year": "2010"
    },
    {
      "DOI": "10.1016/B978-0-444-62702-5.00005-6",
      "author": "DGR Evans",
      "doi-asserted-by": "publisher",
      "first-page": "87",
      "journal-title": "Handb Clin Neurol.",
      "key": "892_CR7",
      "unstructured": "Evans DGR. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87–96.",
      "volume": "132",
      "year": "2015"
    },
    {
      "key": "892_CR8",
      "unstructured": "Evans DG, Huson S, Legius E, Messiaen LM, Plotkin SR, Wolkenstein P. Revision of the diagnostic criteria of the neurofibromatoses. NF Conference. 2019. https://www.ctf.org/images/uploads/documents/Revised_Diagnostic_Criteria_for_Experts_2019_09_21_(1).pdf"
    },
    {
      "DOI": "10.1111/j.1365-2648.1994.tb01066.x",
      "author": "PL Williams",
      "doi-asserted-by": "publisher",
      "first-page": "180",
      "journal-title": "J Adv Nurs.",
      "key": "892_CR9",
      "unstructured": "Williams PL, Webb C. The Delphi technique: a methodological discussion. J Adv Nurs. 1994;19:180–6.",
      "volume": "19",
      "year": "1994"
    },
    {
      "DOI": "10.1186/1471-2288-5-37",
      "author": "RB Akins",
      "doi-asserted-by": "publisher",
      "journal-title": "BMC Med Res Methodol.",
      "key": "892_CR10",
      "unstructured": "Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005;5:37.",
      "volume": "5",
      "year": "2005"
    },
    {
      "key": "892_CR11",
      "unstructured": "NF Patients United: Global network of neurofibromatosis patient organisations. 2021. https://www.nf-patients.eu/."
    },
    {
      "key": "892_CR12",
      "unstructured": "Children’s Tumor Foundation. 2021. https://www.ctf.org/."
    },
    {
      "DOI": "10.1016/j.eujim.2015.07.002",
      "author": "EG Trevelyan",
      "doi-asserted-by": "publisher",
      "first-page": "423",
      "journal-title": "Eur J Integr Med.",
      "key": "892_CR13",
      "unstructured": "Trevelyan EG, Robinson PN. Delphi methodology in health research: how to do it? Eur J Integr Med. 2015;7:423–8.",
      "volume": "7",
      "year": "2015"
    },
    {
      "author": "MK Murphy",
      "first-page": "i",
      "journal-title": "Health Technol Assess",
      "key": "892_CR14",
      "unstructured": "Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i–iv. 1–88.",
      "volume": "2",
      "year": "1998"
    },
    {
      "DOI": "10.1097/ACM.0000000000001812",
      "author": "S Humphrey-Murto",
      "doi-asserted-by": "publisher",
      "first-page": "1491",
      "journal-title": "Acad Med.",
      "key": "892_CR15",
      "unstructured": "Humphrey-Murto S, Varpio L, Wood TJ, Gonsalves C, Ufholz LA, Mascioli K, et al. The use of the Delphi and other consensus group methods in medical education research: a review. Acad Med. 2017;92:1491–8.",
      "volume": "92",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.2015.65.3576",
      "author": "E Uusitalo",
      "doi-asserted-by": "publisher",
      "first-page": "1978",
      "journal-title": "J Clin Oncol",
      "key": "892_CR16",
      "unstructured": "Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34:1978–86.",
      "volume": "34",
      "year": "2016"
    },
    {
      "DOI": "10.1002/pbc.22462",
      "author": "AJ Huttner",
      "doi-asserted-by": "crossref",
      "first-page": "890",
      "journal-title": "Pediatr Blood Cancer",
      "key": "892_CR17",
      "unstructured": "Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, et al. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010;54:890–6.",
      "volume": "54",
      "year": "2010"
    },
    {
      "DOI": "10.1002/1097-0142(19900615)65:12\u003c2771::AID-CNCR2820651227\u003e3.0.CO;2-J",
      "author": "MJ Marchese",
      "doi-asserted-by": "publisher",
      "first-page": "2771",
      "journal-title": "Cancer.",
      "key": "892_CR18",
      "unstructured": "Marchese MJ, Chang CH. Malignant astrocytic gliomas in children. Cancer. 1990;65:2771–8.",
      "volume": "65",
      "year": "1990"
    },
    {
      "DOI": "10.1007/BF00165101",
      "author": "R Sposto",
      "doi-asserted-by": "publisher",
      "first-page": "165",
      "journal-title": "J Neurooncol.",
      "key": "892_CR19",
      "unstructured": "Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7:165–77.",
      "volume": "7",
      "year": "1989"
    },
    {
      "DOI": "10.1056/NEJMra0708126",
      "author": "PY Wen",
      "doi-asserted-by": "publisher",
      "first-page": "492",
      "journal-title": "N Engl J Med.",
      "key": "892_CR20",
      "unstructured": "Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.",
      "volume": "359",
      "year": "2008"
    },
    {
      "DOI": "10.3174/ajnr.A5368",
      "author": "N Verburg",
      "doi-asserted-by": "publisher",
      "first-page": "1884",
      "journal-title": "AJNR Am J Neuroradiol.",
      "key": "892_CR21",
      "unstructured": "Verburg N, Hoefnagels FWA, Barkhof F, Boellaard R, Goldman S, Guo J, et al. Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: a meta-analysis. AJNR Am J Neuroradiol. 2017;38:1884–91.",
      "volume": "38",
      "year": "2017"
    },
    {
      "DOI": "10.1212/01.wnl.0000179303.72345.ce",
      "author": "SL Hyman",
      "doi-asserted-by": "publisher",
      "first-page": "1037",
      "journal-title": "Neurology.",
      "key": "892_CR22",
      "unstructured": "Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology. 2005;65:1037–44.",
      "volume": "65",
      "year": "2005"
    },
    {
      "DOI": "10.3389/fped.2017.00227",
      "author": "MM Torres Nupan",
      "doi-asserted-by": "publisher",
      "first-page": "227",
      "journal-title": "Front Pediatr.",
      "key": "892_CR23",
      "unstructured": "Torres Nupan MM, Velez Van Meerbeke A, López Cabra CA, Herrera, Gomez PM. Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatr. 2017;5:227.",
      "volume": "5",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s11136-018-2055-5",
      "author": "JW Varni",
      "doi-asserted-by": "publisher",
      "first-page": "1047",
      "journal-title": "Qual Life Res.",
      "key": "892_CR24",
      "unstructured": "Varni JW, Nutakki K, Swigonski NL. Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1. Qual Life Res. 2019;28:1047–52.",
      "volume": "28",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s11060-015-1725-1",
      "author": "AM Vranceanu",
      "doi-asserted-by": "publisher",
      "first-page": "219",
      "journal-title": "J Neurooncol",
      "key": "892_CR25",
      "unstructured": "Vranceanu AM, Merker VL, Park ER, Plotkin SR. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015;122:219–28.",
      "volume": "122",
      "year": "2015"
    },
    {
      "DOI": "10.1212/WNL.0000000000003435",
      "author": "JM Payne",
      "doi-asserted-by": "publisher",
      "first-page": "2575",
      "journal-title": "Neurology.",
      "key": "892_CR26",
      "unstructured": "Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJ, Cutter G, et al. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016;87:2575–84.",
      "volume": "87",
      "year": "2016"
    },
    {
      "DOI": "10.1186/s13229-018-0190-z",
      "author": "S Stivaros",
      "doi-asserted-by": "publisher",
      "journal-title": "Mol Autism",
      "key": "892_CR27",
      "unstructured": "Stivaros S, Garg S, Tziraki M, Cai Y, Thomas O, Mellor J, et al. Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Mol Autism. 2018;9:12.",
      "volume": "9",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1474-4422(13)70227-8",
      "author": "T van der Vaart",
      "doi-asserted-by": "publisher",
      "first-page": "1076",
      "journal-title": "Lancet Neurol",
      "key": "892_CR28",
      "unstructured": "van der Vaart T, Plasschaert E, Rietman AB, Renard M, Oostenbrink R, Vogels A, et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12:1076–83.",
      "volume": "12",
      "year": "2013"
    }
  ],
  "reference-count": 28,
  "references-count": 28,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-021-00892-z"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Identifying challenges in neurofibromatosis: a modified Delphi procedure"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "29"
}